Treating bacterial infections with bacteriophages in the 21st century

Southern African Journal of Infectious Diseases

 
 
Field Value
 
Title Treating bacterial infections with bacteriophages in the 21st century
 
Creator Opperman, Christoffel J. Wojno, Justyna M. Brink, Adrian J.
 
Subject — bacteriophage; bacteriophage therapy; phage; non-lytic phage; vaccination; gene-transfer; endolysins; enzybiotics; artilysins
Description Bacteriophages (phages) were discovered in the early part of the 20th century, and their ability to eliminate bacterial infections as bacterial viruses gathered interest almost immediately. Bacteriophage therapy was halted in the Western world due to inconclusive results in early experiments and the concurrent discovery of antibiotics. The spread of antibiotic-resistant bacteria has elicited renewed interest in bacteriophages as a natural alternative to conventional antibiotic therapy. Interest in the application of bacteriophages has also expanded to include the environment, such as wastewater treatment, agriculture and aquaculture. Although the complete phage is important in bacteriophage therapy, the focus is shifting to purified phage enzymes. These enzymes are an attractive option for pharmaceutical companies with their patent potential. They can be bio-engineered for enhanced adjuvant properties, such as a broadened spectrum of activity or binding capability. Enzymes also eliminate the concern that the prophage might integrate resistance genes into the bacterial genome. From a clinical perspective, the first randomised clinical controlled phage therapy trial was conducted with more pioneering phase I/II clinical studies on the horizon. In this opinion paper, the authors outline bacteriophages as naturally occurring bactericidal entities, their therapeutic potential against antibiotic-resistant bacteria and compare them to antibiotics. Their potential multipurpose application in the medical field is also addressed, including the use of bacteriophages for vaccination, and utilisation of the antimicrobial enzymes that they produce.
 
Publisher AOSIS Publishing
 
Contributor None
Date 2022-03-29
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — —
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/sajid.v37i1.346
 
Source Southern African Journal of Infectious Diseases; Vol 37, No 1 (2022); 7 pages 2313-1810 2312-0053
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://sajid.co.za/index.php/sajid/article/view/346/923 https://sajid.co.za/index.php/sajid/article/view/346/924 https://sajid.co.za/index.php/sajid/article/view/346/925 https://sajid.co.za/index.php/sajid/article/view/346/926
 
Coverage — — —
Rights Copyright (c) 2022 Christoffel Johannes Opperman, Justyna Maria Wojno, Adrian John Brink https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT